Abbott's Trading Volume Surges 64% to 11.14 Billion Ranking 71st in Market

On May 15, 2025, Abbott's trading volume reached 11.14 billion, marking a 64.26% increase from the previous day, ranking 71st in the day's stock market. Abbott (ABT) rose by 3.73%.

Abbott Laboratories recently announced positive data from the REFLECT studies, which focused on its FreeStyle Libre continuous glucose monitoring (CGM) technology. The studies, funded by Abbott, were conducted using data from the Swedish National Diabetes Register (NDR). The results showed that the use of Libre technology reduced cardiovascular disease-related hospitalizations by 78% for people living with Type 1 diabetes who had prior severe low blood sugar episodes. Similar reductions in heart-related hospitalizations were observed for those with Type 2 diabetes on insulin using Libre biowearable technology.

Abbott's FreeStyle Libre technology has been recognized for its significant impact on reducing hospitalizations related to cardiovascular disease. The technology has shown a 78% reduction in such hospitalizations for individuals with Type 1 diabetes who have experienced severe low blood sugar episodes. Additionally, the technology has demonstrated a similar reduction in heart-related hospitalizations for those with Type 2 diabetes who are on insulin.

Abbott Laboratories has reported strong first-quarter sales and earnings per share (EPS) growth, driven by its diversified business model. The company's Medical Devices segment, particularly the Continuous Glucose Monitoring (CGM) division, showed notable strength with organic sales growth of 12.6%, fueled by a 30% increase in U.S. CGM sales.